Videoaufzeichnung des Events
Forschung im Bereich der öffentlichen Gesundheit und gemeinsame Nutzung von Daten
Wie sieht die künftige Gesundheitsdatenlandschaft in Europa aus und wie müssen Infrastruktur, Technologie und Interoperabilität für datengeschützte Rahmenwerke beschaffen sein? Wie funktionieren Zusammenarbeit und Datenaustausch um Fortschritte in der Präzisionsmedizin zu erzielen? Sehen Sie hier beide Teile der Aufzeichnung mit anschließenden Diskussionen und Wrap-ups. Sie können sich weiter unten auch alle Vorträge/ Diskussionen einzeln ansehen.
Veröffentlicht:For the past 10 years Martin has been focused on bringing innovation to cancer patients and held various positions in the pharmaceutical industry. In his present role he is heading personalized healthcare in Medical Affairs at Roche Germany.
She was Editor in Chief of „Pathobiology“ until 2020 and the Co-Editor of „Journal of Public Health Policy“. In addition to her academic work she acts as the Director and Head of the World Federation of Public Health Associations and holds positions at several Committees of Public Health oriented institutions. She was president of Europa Donna – The European Breast Cancer Forum and Founding President of the Swiss Forum of Europa Donna. She teaches at the University of Geneva, the Swiss School of Public Health and she also teaches patient support groups. She is (co)author of over 120 scientific papers.
She studied political sciences and EU affairs, with a specialisation at the College of Europe in the law and economics of internal market. She has a PhD in international relations.
Mr. Kalliola holds a positions of trust in HMA-EMA joint big data steering group, HMA-EMA Darwin EU advisory board and DNV Digital health advisory board.
1. Delivered EU and country Government Affairs strategy to successfully bringing 22 Member State to sign up the Million European Genome Declaration
2. Built a stakeholders affairs strategy to gain the support of 28 Member states that personalised medicine/healthcare should be a priority through the EU Council Conclusion on Personalised Medicine and Patient Access
3. Delivered successful Stakeholders strategy to improve cross border healthcare through the realisation of the EU Directive
4. Drove forward the stakeholders support for a public-private policy framework to support the Innovation Medicine Initiative (IMI I) to be transformed into IMI II - increasing this funding to 3.5 billion Euros.
5. Published over 50 academic publications in the area of personalise healthcare
Prior to setting up EAPM, Denis worked as the Brussels Director of the European Cancer Patient Coalition from 2009, as a policy advisor in the European Parliament on a broad array of health issues relating to the pharmaceutical area, access to healthcare and patient issues. Additionally, he has worked in international NGOs on health development projects in Afghanistan, Mexico and Palestine related to issues on health governance, education, HIV/AIDS awareness and access to healthcare
He is former chair of the Dutch Medical Oncology Society and former board member of the EORTC and chair of the EORTC Soft Tissue and Bone Sarcoma Group. He was invited as one of the co-chairs of the Dutch molecular matched therapy DRUP study.